For example, the BRAFV600E/K mutation is a predictive biomarker for MEK inhibitor sensitivity across multiple tumor types, but not within melanoma cell lines specifically (Iorio et al, 2016), although BRAFV600E/K is predominantly found in melanoma (Hodis et al, 2012). This evidence concerns the gene MAP2K7 and neoplasm.